Neuron23 logo

Neuron23

Combining cutting-edge science, human genetics, and a patient-centered approach to transform how we treat Parkinson’s.

28 employees · est. 2018 · South San Francisco, United...

VS
Satori Pharmaceuticals logo

Satori Pharmaceuticals

Pioneering advanced therapies for Alzheimer's, Parkinson's, and other neurodegenerative diseases.

est. 2005

Satori Pharmaceuticals is the older company (2018 vs 2005).

Side-by-Side Comparison

Neuron23 Satori Pharmaceuticals
Founded
2018 2005 older
Headquarters
South San Francisco, United States Not tracked yet
Employees
28 Not tracked yet
Industry
Not tracked yet Health Care, Pharmaceutical
Funding Stage
Series D Series Unknown
Total Funding
$230.00M $47.32M
Funding Rounds
4 5
Services
Development of precision medicine for Parkinson's Disease, Clinical trials for novel therapeutic approaches, Research and development in neuroimmunology and neuroscience Not tracked yet
Target Customers
Patients with Parkinson's Disease, Healthcare providers specializing in neurology, Pharmaceutical and biotechnology investors Not tracked yet
Taxonomy
Precision Medicine, Parkinson's Disease, Neurodegenerative Diseases, Human Genetics, Biomarker Platform, Drug Discovery, Neurological Diseases, Alzheimer's Disease, Clinical-stage Biotechnology, Hyperactive LRRK2, Patient-centered Approach, Neuroinflammatory Diseases, Autoimmune Diseases Neuroscience, Alzheimer's, Parkinson's, Disease-modifying Therapies, Neurodegenerative Diseases, Pharmaceuticals, Drug Discovery, Disease Research, Neurological Disorders
Website
neuron23.com satoripharma.com
Neuron23 logo

About Neuron23

Neuron23, founded in 2018, is a clinical-stage biotechnology company based in the United States. The company is pioneering advancements in precision medicine, specifically targeting Parkinson’s disease driven by hyperactive LRRK2. By integrating cutting-edge science with human genetics and its propr...

Satori Pharmaceuticals logo

About Satori Pharmaceuticals

Satori Pharmaceuticals, founded in 2005, is a neuroscience company dedicated to pioneering advanced therapies for Alzheimer's, Parkinson's, and other neurodegenerative diseases. The company's slogan, "Pioneering advanced therapies for Alzheimer's, Parkinson's, and other neurodegenerative diseases,"...

We will tell you when either one moves

BounceWatch watches Neuron23 and Satori Pharmaceuticals for new funding, fast hiring, new executives and a change of software vendor. When one happens, we email you the same day.

Watch both — free

Funding, hiring, leadership and stack changes at Neuron23 and Satori Pharmaceuticals — by email.

Frequently Asked Questions

Neuron23 — Combining cutting-edge science, human genetics, and a patient-centered approach to transform how we treat Parkinson’s.. Satori Pharmaceuticals — Pioneering advanced therapies for Alzheimer's, Parkinson's, and other neurodegenerative diseases.. Both companies operate in related markets but may differ in funding stage, team size, and product focus.
Neuron23 has raised $230.00M while Satori Pharmaceuticals has raised $47.32M.
Neuron23 and Satori Pharmaceuticals operate in overlapping markets and are frequently compared. Track both companies on Bounce Watch to monitor their growth signals in real time.

Compare Neuron23 with someone else

Start typing a company name or domain.

Related Comparisons

Compiled from the BounceWatch company index. We last looked at Neuron23 on 31 Mar 2026, and Satori Pharmaceuticals on 12 Sep 2024. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.

One analytics cookie (Google Analytics). Cookie Policy